Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

VitaNova Life Sciences (YJGJ) Net Margin (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Net Margin for 7 consecutive years, with 8.38% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 279.0% year-over-year to 8.38%, compared with a TTM value of 30.9% through Oct 2025, up 1532.0%, and an annual FY2025 reading of 31.96%, up 727.0% over the prior year.
  • Net Margin was 8.38% for Q4 2025 at VitaNova Life Sciences, up from 44.56% in the prior quarter.
  • Across five years, Net Margin topped out at 40.98% in Q2 2025 and bottomed at 245.77% in Q1 2023.
  • Average Net Margin over 5 years is 20.39%, with a median of 14.23% recorded in 2022.
  • The sharpest move saw Net Margin tumbled -27549bps in 2023, then soared 26856bps in 2024.
  • Year by year, Net Margin stood at 33.35% in 2021, then decreased by -22bps to 26.01% in 2022, then plummeted by -662bps to 146.17% in 2023, then skyrocketed by 108bps to 11.18% in 2024, then fell by -25bps to 8.38% in 2025.
  • Business Quant data shows Net Margin for YJGJ at 8.38% in Q4 2025, 44.56% in Q3 2025, and 40.98% in Q2 2025.